Allegro Ophthalmics Raises $23.9 Million

Advised Allegro Ophthalmics in its later stage funding.  The company raised $23.93 million in a combination of convertible debt and promissory note from undisclosed investors. Allegro develops ophthalmic drugs designed for the treatment of wet age-related macular degeneration and provides treatment for diabetic retinopathy and diabetic macular edema.